Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ZYNE | Zynerba Pharmaceuticals Inc

Healthcare | Drug Manufacturers - Specialty & Generic | USA | NASD

Index	-	P/E	-	EPS (ttm)	-0.80	Insider Own	5.51%	Shs Outstand	53.94M	Perf Week	-5.93%
Market Cap	68.50M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	-1.62%	Shs Float	50.97M	Perf Month	-3.79%
Income	-37.58M	PEG	-	EPS next Q	-0.20	Inst Own	19.43%	Short Float / Ratio	0.46% / 0.24	Perf Quarter	285.32%
Sales	0.00M	P/S	-	EPS this Y	-3.96%	Inst Trans	-0.82%	Short Interest	0.23M	Perf Half Y	202.38%
Book/sh	0.54	P/B	2.36	EPS next Y	26.39%	ROA	-69.93%	Target Price	3.17	Perf Year	54.88%
Cash/sh	0.67	P/C	1.90	EPS next 5Y	-	ROE	-87.13%	52W Range	0.25 - 1.40	Perf YTD	139.62%
Dividend	-	P/FCF	-	EPS past 5Y	19.83%	ROI	-129.50%	52W High	-9.29%	Beta	1.32
Dividend %	-	Quick Ratio	3.41	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	408.00%	ATR	0.04
Employees	27	Current Ratio	3.41	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	56.43	Volatility	3.20% 2.29%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	9.71%	Profit Margin	-	Rel Volume	1.33	Prev Close	1.28
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	Payout	-	Avg Volume	971.21K	Price	1.27
Recom	3.00	SMA20	-4.48%	SMA50	32.96%	SMA200	120.44%	Volume	1,294,035	Change	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-20	Reiterated	H.C. Wainwright	Buy	$12 → $9
Jul-01-20	Downgrade	Needham	Buy → Hold
Dec-31-19	Resumed	ROTH Capital	Buy	$12
Oct-21-19	Initiated	Needham	Buy	$18
Apr-22-19	Resumed	Canaccord Genuity	Buy
Feb-01-18	Resumed	H.C. Wainwright	Buy	$23
Jan-29-18	Initiated	Ladenburg Thalmann	Buy	$25.50
Jan-26-18	Initiated	Seaport Global Securities	Buy	$16
Oct-02-17	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4 → $17
Sep-29-17	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-15-17	Upgrade	ROTH Capital	Neutral → Buy
Aug-15-17	Downgrade	Oppenheimer	Outperform → Perform
Aug-15-17	Downgrade	Jefferies	Buy → Hold
Aug-08-17	Downgrade	ROTH Capital	Buy → Neutral
Aug-08-17	Downgrade	H.C. Wainwright	Buy → Neutral	$7
Aug-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-07-17	Downgrade	Maxim Group	Buy → Hold
Aug-07-17	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$28 → $4
Mar-28-17	Reiterated	H.C. Wainwright	Buy	$22 → $30
Feb-24-17	Initiated	Maxim Group	Buy	$32

Show Previous Ratings

Today 08:00AM	HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. (PR Newswire)
Sep-25-23 10:41AM	Short seller petitions FDA to reverse approval of Harmony Biosciences drug (American City Business Journals)
Sep-14-23 11:01PM	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc (GuruFocus.com)
04:15PM	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium (GlobeNewswire)
Aug-14-23 11:06AM	Harmony Biosciences to acquire Main Line's Zynerba in up to $200M deal (American City Business Journals) +298.23%
09:02AM	Loading…
09:02AM	Zynerba: Q2 Earnings Snapshot (AP Finance)
07:30AM	HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. (PR Newswire)
Aug-08-23 04:05PM	Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting (GlobeNewswire)
Jul-25-23 05:18PM	Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting (GlobeNewswire)
Jun-29-23 12:00PM	Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jun-28-23 04:05PM	Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting (GlobeNewswire)
Jun-20-23 07:00AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (GlobeNewswire)
Jun-13-23 04:05PM	Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting (GlobeNewswire)
May-23-23 07:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
May-18-23 10:05AM	Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To Profitability (Simply Wall St.)
07:12AM	Loading…
May-15-23 07:12AM	Zynerba: Q1 Earnings Snapshot (AP Finance)
07:00AM	Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Apr-12-23 07:30AM	Zynerba Pharmaceuticals Presents Data on Zygel at the 55th Gatlinburg Conference (GlobeNewswire)
Apr-05-23 07:30AM	Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference (GlobeNewswire)
Mar-28-23 07:35AM	Zynerba: Q4 Earnings Snapshot (AP Finance)
07:30AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire)
Mar-13-23 04:15PM	Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank (GlobeNewswire)
Mar-07-23 07:00AM	Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Mar-01-23 07:00AM	Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-11-23 08:30AM	Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome (GlobeNewswire)
Jan-08-23 09:56AM	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-21-22 07:29AM	UPDATE 2-Zynerba delays genetic disorder drug data on enrollment challenge (Reuters)
07:00AM	Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome (GlobeNewswire)
Dec-05-22 07:30AM	Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology (GlobeNewswire)
Nov-29-22 07:00AM	Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology (GlobeNewswire) -5.28%
07:30AM	Loading…
Nov-28-22 07:30AM	Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel in the Journal of Neurodevelopmental Disorders (GlobeNewswire) +6.44%
Nov-15-22 07:30AM	Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel in 22q11.2 Deletion Syndrome (GlobeNewswire)
Nov-14-22 07:30AM	Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights (GlobeNewswire)
Nov-02-22 07:30AM	Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel for the Treatment of 22q11.2 Deletion Syndrome (GlobeNewswire)
Oct-17-22 07:00AM	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit (GlobeNewswire)
Oct-10-22 07:00AM	Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit (GlobeNewswire) -5.57%
Oct-06-22 07:00AM	Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel (GlobeNewswire) +13.01%
Sep-29-22 07:00AM	Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire) -9.10%
Sep-22-22 07:00AM	Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-08-22 09:15AM	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium (GlobeNewswire) +5.36%
Sep-06-22 07:00AM	Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 07:00AM	Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium (GlobeNewswire)
Aug-10-22 07:00AM	Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights (GlobeNewswire)
Aug-03-22 07:00AM	Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Aug-01-22 07:11AM	We're Hopeful That Zynerba Pharmaceuticals (NASDAQ:ZYNE) Will Use Its Cash Wisely (Simply Wall St.)
Jul-21-22 07:00AM	Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital (GlobeNewswire) +9.57%
Jul-07-22 07:00AM	Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference (GlobeNewswire)
Jun-24-22 01:19PM	Lab Notes: AmerisourceBergen aims to help cell and gene therapy developers, Penn spinout expands research deal with university (American City Business Journals)
Jun-22-22 10:39AM	Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease (Benzinga)
Jun-21-22 08:05PM	Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel in 22q11.2 Deletion Syndrome (GlobeNewswire)
Jun-01-22 07:00AM	Zynerba Pharmaceuticals Presents Data on Zygel at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire) -5.48%
May-24-22 07:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire) -7.83%
May-17-22 07:00AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.80%
May-16-22 07:00AM	Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights (GlobeNewswire) +8.68%
May-11-22 01:30PM	Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting (GlobeNewswire) -12.83%
May-09-22 04:57PM	Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting (GlobeNewswire) -8.80%
May-02-22 07:00AM	Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting (GlobeNewswire)
Apr-21-22 07:00AM	Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting (GlobeNewswire)
Apr-05-22 07:00AM	Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference (GlobeNewswire) -5.34%
Mar-22-22 07:00AM	Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit (GlobeNewswire) +6.15%
Mar-08-22 10:00AM	Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-04-22 02:34PM	Lab notes: Myonex acquires German drug business; Vallon receives Covid drug treatment patent (American City Business Journals)
Mar-01-22 06:00AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights (GlobeNewswire)
Feb-28-22 04:05PM	Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel in Fragile X Syndrome (GlobeNewswire)
07:00AM	Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome (GlobeNewswire)
Feb-22-22 05:13AM	Companies Like Zynerba Pharmaceuticals (NASDAQ:ZYNE) Are In A Position To Invest In Growth (Simply Wall St.) -5.24%
Feb-15-22 07:00AM	Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer (GlobeNewswire)
Feb-10-22 07:00AM	Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-06-22 07:00AM	Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Jan-05-22 06:29AM	Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders (Benzinga) -9.15%
Jan-04-22 04:05PM	Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE (GlobeNewswire)
Dec-06-21 07:00AM	Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium (GlobeNewswire)
Nov-22-21 07:00AM	Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel (GlobeNewswire)
Nov-15-21 07:00AM	Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights (GlobeNewswire)
Oct-21-21 07:00AM	Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October (GlobeNewswire)
Oct-19-21 04:15PM	Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit (GlobeNewswire)
Oct-08-21 07:30AM	Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition (GlobeNewswire)
Sep-20-21 07:00AM	Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-13-21 07:00AM	Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome (GlobeNewswire)
Sep-09-21 11:06AM	Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children (Benzinga) +5.32%
07:00AM	Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 (GlobeNewswire)
Sep-07-21 07:00AM	Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open (GlobeNewswire)
Sep-02-21 07:30AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.34%
07:00AM	Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 (GlobeNewswire)
Aug-09-21 07:00AM	Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights (GlobeNewswire)
Aug-04-21 07:30AM	Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference (GlobeNewswire)
Aug-02-21 01:31PM	10 Best CBD Stocks to Invest In (Insider Monkey)
Jul-07-21 07:30AM	Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference (GlobeNewswire)
Jun-30-21 07:00AM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting (GlobeNewswire)
Jun-29-21 09:01AM	Should I Buy Zynerba Pharmaceuticals Inc (ZYNE)? (Insider Monkey)
Jun-11-21 02:44PM	Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies (Benzinga)
12:30PM	Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting (GlobeNewswire)
Jun-09-21 04:05PM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting (GlobeNewswire)
Jun-07-21 08:00AM	Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. ZYNE (GlobeNewswire)
Jun-04-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting (GlobeNewswire)
Jun-03-21 10:00AM	Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-27-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-26-21 07:30AM	Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.45%
07:00AM	Notice of Settlement of Derivative Actions (GlobeNewswire)
May-17-21 08:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference (GlobeNewswire)

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANIDO ARMANDO	Chairman & Chief Exec. Officer	Sep 13	Sale	1.33	17,830	23,637	936,722	Sep 14 04:13 PM
Sebree Terri B	President	Sep 13	Sale	1.33	12,401	16,440	596,241	Sep 14 04:14 PM
Fickenscher James E	Chief Financial Officer	Sep 13	Sale	1.33	8,998	11,929	378,087	Sep 14 04:13 PM
Rosenberger Brian	VP, Commercial & Business Dev.	Sep 13	Sale	1.33	6,411	8,499	249,559	Sep 14 04:14 PM
Jones Kenneth T	See Remarks	Sep 13	Sale	1.33	2,505	3,321	85,520	Sep 14 04:13 PM
KISNER DANIEL L	Director	Jun 14	Sale	0.35	115	40	75,778	Jun 15 04:29 PM
MOCH KENNETH I	Director	Jun 14	Sale	0.35	115	40	75,778	Jun 15 04:30 PM
Stephenson Pamela	Director	Jun 14	Sale	0.35	115	40	75,778	Jun 15 04:30 PM
COOPER WARREN D	Director	Jun 14	Sale	0.35	115	40	75,778	Jun 15 04:28 PM
Butler John P.	Director	Jun 14	Sale	0.35	115	40	80,765	Jun 15 04:28 PM
FEDERICI WILLIAM J	Director	Jun 14	Sale	0.35	115	40	75,778	Jun 15 04:29 PM
Parker Albert P	Chief Legal Officer	Feb 15	Sale	0.54	3,173	1,719	227,018	Feb 17 04:21 PM
ANIDO ARMANDO	Chairman & Chief Exec. Officer	Jan 23	Sale	0.60	35,453	21,194	576,235	Jan 25 05:25 PM
Sebree Terri B	President	Jan 23	Sale	0.60	24,661	14,742	343,204	Jan 25 05:29 PM
Fickenscher James E	Chief Financial Officer	Jan 23	Sale	0.60	17,769	10,622	154,736	Jan 25 05:28 PM
Rosenberger Brian	VP, Commercial & Business Dev.	Jan 23	Sale	0.60	12,663	7,570	94,848	Jan 25 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZYNE | Zynerba Pharmaceuticals Inc

Upgrade your FINVIZ experience